secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verrica Pharmaceuticals Inc. (VRCA)
CIK:        0001660334
Form:       8-K
Filed at:   2025-02-21T23:59:59+00:00
Accession:  0001193125-25-032003
Event type: leadership
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Verrica enters lender waiver of going concern covenants for FY2024, Q1 2025
---------------------------------------------------------------------------

- Lenders waive covenant requiring no going concern qualification in Dec 2024 and Mar 2025 financials.
- Waiver is with OrbiMed Royalty & Credit Opportunities IV, LP under Credit Agreement dated July 2023.
- Remaining terms of Credit Agreement unchanged; waiver filed with 10-K.
- This indicates auditor likely issued going concern opinion, signaling potential financial distress.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525032003/0001193125-25-032003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1660334/000119312525032003/d812932d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-032003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer